By hitting
breast cancer cells with a targeted therapeutic
immediately after chemotherapy, researchers from Brigham and Women's Hospital (BWH) were able to target
cancer cells during a transitional stage when they were most vulnerable, killing cells and shrinking tumors in the lab and in pre-clinical models.
By hitting
breast cancer cells with a targeted therapeutic
immediately after chemotherapy, researchers were able to target
cancer cells during a transitional stage when they were most vulnerable.